Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2009 | 1 |
2010 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6. doi: 10.1097/qai.0b013e3181e2cba0.
J Acquir Immune Defic Syndr. 2010.
PMID: 20672447
Free PMC article.
Clinical Trial.
BACKGROUND: Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity. METHODS: Phase 2, double-blind, randomized study of vicriviroc in treatment-experienced subjects with CCR5-using HIV-1. ...
BACKGROUND: Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity. METHODS: Phas …
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L.
Findling RL, et al.
J Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):583-94; quiz 632. doi: 10.1016/j.jaac.2010.03.013. Epub 2010 May 1.
J Am Acad Child Adolesc Psychiatry. 2010.
PMID: 20494268
Free PMC article.
Clinical Trial.
OBJECTIVE: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. ...
OBJECTIVE: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. ...
Item in Clipboard
Emerging drugs for atopic dermatitis.
Ong PY.
Ong PY.
Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79. doi: 10.1517/14728210902721248.
Expert Opin Emerg Drugs. 2009.
PMID: 19216704
Review.
Preventive treatment of AD consists of daily skin hydration and emollient therapy; but the majority of patients still require symptomatic treatment with topical corticosteroids and/or topical calcineurin inhibitors, both of which may be associated with potential long-term …
Preventive treatment of AD consists of daily skin hydration and emollient therapy; but the majority of patients still require symptomatic tr …
Item in Clipboard
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.
Gulick RM, et al.
J Infect Dis. 2007 Jul 15;196(2):304-12. doi: 10.1086/518797. Epub 2007 Jun 5.
J Infect Dis. 2007.
PMID: 17570119
Clinical Trial.
BACKGROUND: Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study. METHODS: The present study was a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficiency virus (HIV) …
BACKGROUND: Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study. METHOD …
Item in Clipboard
Cite
Cite